Celanese
Celanese's revenue fell 7.0% to $9.5 billion in fiscal 2025. Its operating margin was −8.2%, down from −7.0% a year earlier. Free cash flow was $803 million, up 51.2%. It paid out $13 million in dividends and buybacks, 2% of free cash flow. The diluted share count rose 0.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2023, earnings per share grew 16.3% a year and net income 11.6% a year, as buybacks cut the share count by 25%. Celanese then lost money in fiscal 2024 and 2025.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Celanese yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Celanese's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Celanese's fiscal 2025 free cash flow of $803M, net cash of −$11.5B at December 31, 2025 and 110 million diluted shares, from its filings. The scenarios are fitted to Celanese: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, -0.4% a year, kept between 0% and 20%; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 13%: 11% for a cyclical or higher-risk business (Specialty Chemicals), plus 1 point as a smaller company, worth $5.3B, plus 1 point for unsteady results (a loss in fiscal 2025); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target. A negative value means Celanese's net debt is larger than what that scenario's cash flows are worth today.
- Last close, October 26, 2026
- $48.08
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
The P/E method needs positive earnings, and Celanese's latest diluted earnings per share were negative or zero.
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 546 | 1,508 | 1,805 | 962 | 1,263 |
| Debt incl. finance leases | 3,959 | 14,625 | 13,694 | 12,725 | 12,790 |
| Net debt (negative means net cash) | 3,413 | 13,117 | 11,889 | 11,763 | 11,527 |
| Net debt to EBITDA | 1.5x | 7.1x | 5.0x | 145.2x | — |
| Debt to equity | 0.9x | 2.6x | 1.9x | 2.5x | 3.2x |
| Interest coverage | 21.4x | 3.4x | 2.3x | −1.1x | −1.1x |
| Current ratio | 1.5x | 1.6x | 1.5x | 1.3x | 1.6x |
| Quick ratio | 0.9x | 0.9x | 0.9x | 0.7x | 0.9x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, 4 insiders bought $593,258 of Celanese shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Chuck KyrishSVP & CFO | Bought | 2,300 | $45.52 | $104,701 | Form 4 |
| Aug 11, 2026 | Mark Christopher MurraySVP - Acetyls | Bought | 2,153 | $45.52 | $98,005 | Form 4 |
| Aug 11, 2026 | Ashley B DuffieSVP & GC | Bought | 600 | $45.60 | $27,360 | Form 4 |
| Dec 10, 2025 | Scott A RichardsonCEO & President, Director | Bought | 3,800 | $41.59 | $158,042 | Form 4 |
| Dec 9, 2025 | Chuck KyrishSVP & CFO | Bought | 5,000 | $41.03 | $205,150 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Pass | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 3 of 9 | 4 of 9 | 5 of 9 |
| Accruals ratio | 0.2% | −10.2% | −10.4% |
Compare
Put Celanese side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Celanese | FY25 | −7.0% | −8.2% | 8.4% | −3.7% | — | 5 | |
| Eastman Chemical | FY25 | −6.7% | — | 4.8% | 6.5% | 3.3x | 5 | Compare |
| International Flavors & Fragrances | FY25 | −5.2% | −3.5% | 2.4% | −1.4% | 9.4x | 6 | Compare |
| Westlake | FY25 | −8.0% | −14.1% | −4.7% | −10.0% | — | 3 | Compare |
| RPM International | FY26 | 6.7% | — | 8.6% | 13.9% | 1.9x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 5,389 | 6,140 | 7,155 | 6,297 | 5,655 | 8,537 | 9,673 | 10,926 | 10,268 | 9,544 |
| Revenue growth | −5.0% | 13.9% | 16.5% | −12.0% | −10.2% | 51.0% | 13.3% | 12.9% | −6.0% | −7.0% |
| Gross profit | 1,405 | 1,511 | 1,972 | 1,606 | 1,293 | 2,682 | 2,380 | 2,583 | 2,336 | 1,952 |
| Research and development | 78 | 73 | 72 | 67 | 74 | 86 | 112 | 146 | 130 | 125 |
| Operating income | 934 | 857 | 1,334 | 834 | 664 | 1,946 | 1,378 | 1,665 | −720 | −786 |
| Net income | 900 | 843 | 1,207 | 852 | 1,985 | 1,890 | 1,894 | 1,943 | −1,542 | −1,165 |
| Diluted EPS (US$) | 6.18 | 6.09 | 8.91 | 6.84 | 16.75 | 16.86 | 17.34 | 17.76 | −14.11 | −10.64 |
| Diluted shares (millions) | 146 | 138 | 135 | 125 | 118 | 112 | 109 | 109 | 109 | 110 |
| Cash flow | ||||||||||
| Cash from operations | 893 | 803 | 1,558 | 1,454 | 1,343 | 1,757 | 1,819 | 1,899 | 966 | 1,146 |
| Capital expenditure | 246 | 267 | 337 | 370 | 364 | 467 | 543 | 568 | 435 | 343 |
| Free cash flow | 647 | 536 | 1,221 | 1,084 | 979 | 1,290 | 1,276 | 1,331 | 531 | 803 |
| Dividends paid | 201 | 241 | 280 | 300 | 293 | 304 | 297 | 305 | 307 | 13 |
| Share buybacks | 500 | 500 | 805 | 996 | 650 | 1,000 | 17 | 0 | 0 | 0 |
| Acquisitions | 178 | 269 | 144 | 91 | 100 | 1,142 | 10,589 | 52 | 0 | 0 |
| Stock-based compensation | 31 | 47 | 71 | 48 | 28 | 95 | 60 | 40 | 32 | 24 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 668 | 608 | 470 | 503 | 1,488 | 546 | 1,508 | 1,805 | 962 | 1,263 |
| Debt incl. finance leases | 3,006 | 3,484 | 3,599 | 3,680 | 3,937 | 3,959 | 14,625 | 13,694 | 12,725 | 12,790 |
| Total assets | 8,357 | 9,538 | 9,313 | 9,476 | 10,909 | 11,975 | 26,272 | 26,597 | 22,838 | 21,695 |
| Total liabilities | 5,336 | 6,239 | 5,934 | 6,578 | 7,014 | 7,438 | 20,167 | 19,071 | 17,275 | 17,223 |
| Shareholders' equity | 2,588 | 2,887 | 2,984 | 2,507 | 3,526 | 4,189 | 5,637 | 7,065 | 5,129 | 4,049 |
| Margins and ratios | ||||||||||
| Gross margin | 26.1% | 24.6% | 27.6% | 25.5% | 22.9% | 31.4% | 24.6% | 23.6% | 22.8% | 20.4% |
| Operating margin | 17.3% | 14.0% | 18.6% | 13.2% | 11.7% | 22.8% | 14.2% | 15.2% | −7.0% | −8.2% |
| Net margin | 16.7% | 13.7% | 16.9% | 13.5% | 35.1% | 22.1% | 19.6% | 17.8% | −15.0% | −12.2% |
| Free cash flow margin | 12.0% | 8.7% | 17.1% | 17.2% | 17.3% | 15.1% | 13.2% | 12.2% | 5.2% | 8.4% |
| Return on capital | 16.8% | 11.9% | 17.0% | 11.6% | 9.5% | 23.2% | 10.1% | 8.6% | −3.1% | −3.7% |
| Return on equity | 36.2% | 30.8% | 41.1% | 31.0% | 65.8% | 49.0% | 38.5% | 30.6% | −25.3% | −25.4% |
| Return on assets | 10.6% | 9.4% | 12.8% | 9.1% | 19.5% | 16.5% | 9.9% | 7.3% | −6.2% | −5.2% |
| Net debt to EBITDA | 1.9x | 2.5x | 1.9x | 2.7x | 2.4x | 1.5x | 7.1x | 5.0x | 145.2x | — |